Tipranavir

For the clinical treatment of drug-resistant human immunodeficiency virus (HIV) infection, protease inhibitors have always been the core component of combination antiretroviral therapy regimens. Tipranavir is a non-peptide HIV protease inhibitor. It can competitively bind to the active site of viral protease and block the cleavage of Gag and Gag-Pol polyproteins, thereby inhibiting the production of mature infectious viral particles. Compared with traditional peptide protease inhibitors, it still has strong antiviral activity against multi-drug resistant HIV strains. It is mainly used clinically in combination with low-dose ritonavir to treat adult and pediatric HIV-infected patients over 2 years old who have received prior antiretroviral therapy and have HIV protease resistance, providing an important subsequent treatment option for drug-resistant patients.

At present, the global market size of anti-HIV drugs continues to expand, and protease inhibitors still maintain stable demand in drug-resistant treatment scenarios in low- and middle-income countries. There is no verifiable public market size data. In terms of competitive landscape, due to its clinical positioning偏向（哦不对，直接翻，偏向being oriented towards）second-line treatment for drug resistance, there are few overall market participants for tipranavir, and the original research product has long occupied a dominant position. At present, the number of approved generic drugs worldwide is limited, and the supply side is highly concentrated.

The original research enterprise of tipranavir is Boehringer Ingelheim, and the original research brand name is Aptivus. The expiration time of its core compound patent in major markets such as the United States and the European Union is 2017, and the expiration time of the Chinese compound patent is 2016. The dosage forms approved by the original research include oral soft capsules and oral solutions, among which the specification of soft capsules is 250mg, and the specification of oral solution is 100mg/mL. The original research soft capsule has been included in the FDA Reference Listed Drug Catalog, but has not yet been included in the *Chinese List of Chemical Drugs*. Up to now, there is no tipranavir API that has obtained a registration number in China, and no related preparation varieties have been approved for import or domestic marketing. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for tipranavir API, which can cover the whole process requirements such as impurity qualitative analysis, quantitative analysis and stability research in the R&D process. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for the R&D and quality control work of relevant pharmaceutical enterprises.